Optometrists in Hudson, MA Accepting Medicare

10 Optometrists found. Showing 1 - 10

Dr. Saundra Ferrera, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 10 Technology Dr, Hudson, MA 01749 Phone: 978-568-8228    Fax: 978-568-0330

The Eye Care Center, Inc. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 10 Technology Dr, Hudson, MA 01749 Phone: 978-568-8228    Fax: 978-568-0330

Dr. Garrett F. Sullivan, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 34 Pope St, Hudson, MA 01749 Phone: 978-562-7976    Fax: 978-562-4807

Clearsight Eye Care, Inc. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 280 Washington St, Hudson, MA 01749 Phone: 267-808-5011

Malden Eyecare Clinic Llc Optometrist Medicare: Medicare Enrolled Practice Location: 280 Washington St, Inside Wal-mart Vision Center, Hudson, MA 01749 Phone: 978-568-1036    Fax: 978-568-1059

Sullivan Optometry, Pc Optometrist Medicare: Medicare Enrolled Practice Location: 34 Pope St, Hudson, MA 01749 Phone: 978-562-7976    Fax: 978-562-4807

Dr. Daniel G Sullivan, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 34 Pope St, Hudson, MA 01749 Phone: 978-562-7976

Dr. Amie B Adams, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 280 Washington St., Vision Center, Hudson, MA 01749 Phone: 978-568-1036

Dr. Margaret Mary Johnson, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 10 Technology Dr, Hudson, MA 01749 Phone: 508-485-6366    Fax: 978-568-0330

Garrett F. Sullivan Od Optometrist Medicare: Not Enrolled in Medicare Practice Location: 34 Pope St, Hudson, MA 01749 Phone: 978-562-7976    Fax: 978-562-4807

News Archive

Researchers reveal that reduction in mitochondrial DNA may lead to metastasis of breast cancer cells

For years, scientists have observed that tumor cells from certain breast cancer patients with aggressive forms of the disease contained low levels of mitochondrial DNA. But, until recently, no one was able to explain how this characteristic influenced disease progression.

FDA evaluates Phase III randomized trial in acute myeloid leukemia

VION PHARMACEUTICALS, INC., announced today that the U.S. Food and Drug Administration ("FDA") had responded to its Special Protocol Assessment ("SPA") request to evaluate the Phase III randomized trial HOVON AML 92 sponsored by the Dutch-Belgian Cooperative Group for Hematology Oncology ("HOVON") of its lead product Onrigin(TM).

ID Biomedical to supply meningitis C vaccine to the Canadian government

The Canadian government has retained an option to purchase additional product from the Company in the third and final year of the contract. The total value of the contract, including the third year option, could total approximately $30 million to ID Biomedical.

Study findings may lead to new approaches for treating inflammatory diseases

In the body, the immune system often begins its response to various attackers in the same way: the body activates immune cells, so-called phagocytes, which migrate to sites of inflammation caused by, for example, foreign pathogens or damaged tissue.

Read more Medical News

› Verified 1 days ago